|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...106107108109110111112113114115116...156157» |
- | New P4 trial: 6-year Antibody Check After Third Vaccination Against Japanese Encephalitis (clinicaltrials.gov) - Jan 15, 2014
P4, N=60, Not yet recruiting, Sponsor: Medical University of Vienna
- | Xeomin (incobotulinumtoxinA) / Merz Pharma
Enrollment open: Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients (clinicaltrials.gov) - Jan 15, 2014
P4, N=30, Recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
Not yet recruiting --> Recruiting
- PD 360324 / Pfizer
Trial termination: A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Jan 15, 2014
P1, N=28, Terminated, Sponsor: Pfizer
Not yet recruiting --> Recruiting Suspended --> Terminated; See termination reason in detailed description.
- PD 360324 / Pfizer
Enrollment change: A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Jan 15, 2014
P1, N=28, Terminated, Sponsor: Pfizer
Suspended --> Terminated; See termination reason in detailed description. N=48 --> 28
- | ZB-168 / Zura Bio
New P1 trial: A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 15, 2014
P1, N=40, Not yet recruiting, Sponsor: Pfizer
- || Benlysta (belimumab) / GSK
Enrollment closed: A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects (clinicaltrials.gov) - Jan 15, 2014
P1, N=80, Active, not recruiting, Sponsor: GlaxoSmithKline
N=48 --> 28 Recruiting --> Active, not recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Jan 14, 2014
P4, N=20, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- Trial completion: Robot-assisted Gait Training in Multiple Sclerosis Subjects (clinicaltrials.gov) - Jan 14, 2014
P=N/A, N=60, Completed, Sponsor: University Hospital of Ferrara
Not yet recruiting --> Active, not recruiting Recruiting --> Completed
- Trial suspension: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Jan 14, 2014
P2, N=40, Suspended, Sponsor: University Hospital of Ferrara
Recruiting --> Completed Recruiting --> Suspended
- ||||||| tofacitinib / Generic mfg.
Japan: Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan (clinicaltrials.gov) - Jan 14, 2014
P3, N=487, Completed, Sponsor: Pfizer
Recruiting --> Suspended Recruiting --> Completed
- Trial initiation date: Anti-nucleosome B Lymphocytes in Lupus (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=90, Not yet recruiting, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Completed Initiation date: Jul 2013 --> Feb 2014
- Trial initiation date: Trial of a Physical Activity Intervention for RA Fatigue (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=120, Recruiting, Sponsor: University of California, San Francisco
Initiation date: Jul 2013 --> Feb 2014 Initiation date: Jul 2013 --> Nov 2013
- || Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
New P3 trial: OLE Study: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Jan 13, 2014
P3, N=425, Ongoing, Sponsor: Amgen Inc.
- Enrollment open: Trial of a Physical Activity Intervention for RA Fatigue (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=120, Recruiting, Sponsor: University of California, San Francisco
Initiation date: Jul 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- || Orencia (abatacept) / BMS
Enrollment closed: ReACTION: Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting (clinicaltrials.gov) - Jan 13, 2014
P=N/A, N=220, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 13, 2014
P1, N=39, Recruiting, Sponsor: Novo Nordisk
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- New P1/2 trial: Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=8, Recruiting, Sponsor: Germans Trias i Pujol Hospital
- || AMG 811 / Amgen
Enrollment closed: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis (clinicaltrials.gov) - Jan 12, 2014
P1, N=56, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 12, 2014
P1, N=39, Recruiting, Sponsor: Novo Nordisk
- Trial completion, Gene therapy: Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis (clinicaltrials.gov) - Jan 12, 2014
P2, N=10, Completed, Sponsor: Sanjiv Sam Gambhir
Recruiting --> Active, not recruiting Recruiting --> Completed
- | allogeneic human umbilical cord-derived mesenchymal stem cells (huMSC) / Medistem Panama
New P1/2 trial: Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 9, 2014
P1/2, N=20, Recruiting, Sponsor: Translational Biosciences
- || Tresiba (insulin degludec) / Novo Nordisk
New P3 trial: SWITCH 1: A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 9, 2014
P3, N=446, Recruiting, Sponsor: Novo Nordisk A/S
- New P2 trial: The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes (clinicaltrials.gov) - Jan 9, 2014
P2, N=40, Not yet recruiting, Sponsor: Eduardo Ng
- || Ruxience (rituximab-pvvr) / Pfizer
Enrollment closed: Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04) (clinicaltrials.gov) - Jan 9, 2014
P=N/A, N=157, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Enrollment open: The Health Log: A Randomized Clinical Trial (clinicaltrials.gov) - Jan 8, 2014
P=N/A, N=150, Recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Plivensia (sirukumab) / J&J
Enrollment closed, Monotherapy: A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine (clinicaltrials.gov) - Jan 8, 2014
P3, N=122, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 8, 2014
P1, N=46, Recruiting, Sponsor: Novo Nordisk
- ||| RNS60 / Revalesio
Trial initiation date: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 7, 2014
P2, N=270, Not yet recruiting, Sponsor: Revalesio Corporation
Recruiting --> Active, not recruiting Initiation date: Feb 2014 --> Oct 2016
- ||| Tarpeyo (budesonide) / Calliditas, Stada
Enrollment closed: NEFIGAN: The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease (clinicaltrials.gov) - Jan 7, 2014
P2, N=90, Active, not recruiting, Sponsor: Pharmalink AB
Initiation date: Feb 2014 --> Oct 2016 Recruiting --> Active, not recruiting
- Ventolin (albuterol) / GSK
Enrollment change: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Jan 7, 2014
P=N/A, N=21, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting N=50 --> 21
- |||||||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial: TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Na (clinicaltrials.gov) - Jan 7, 2014
P3, N=60, Recruiting, Sponsor: Hoffmann-La Roche
- BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment open: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Jan 7, 2014
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
N=50 --> 21 Not yet recruiting --> Recruiting
- | Ventolin (albuterol) / GSK
Trial completion: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes (clinicaltrials.gov) - Jan 7, 2014
P=N/A, N=21, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| methotrexate / Generic mfg., paracetamol / Generic mfg.
New P2 trial: The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 6, 2014
P2, N=240, Recruiting, Sponsor: Maoxiang Group Jilin Pharmaceutical Co., Ltd.
- Trial withdrawal: Epigenetic Modifications of Diabetes Mellitus Type I (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=0, Withdrawn, Sponsor: Scripps Translational Science Institute
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Epigenetic Modifications of Diabetes Mellitus Type I (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=0, Withdrawn, Sponsor: Scripps Translational Science Institute
Not yet recruiting --> Withdrawn N=50 --> 0
- || Enrollment change: ABACUS: ACCU-CHEK (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=218, Completed, Sponsor: Hoffmann-La Roche
N=50 --> 0 N=285 --> 218
- ARG-301 / arGentis
Enrollment change: Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Jan 6, 2014
P1, N=32, Recruiting, Sponsor: Department of Veterans Affairs
N=285 --> 218 N=42 --> 32
- | BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
New P1 trial: A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog (clinicaltrials.gov) - Jan 6, 2014
P1, N=36, Recruiting, Sponsor: Adocia
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel) (clinicaltrials.gov) - Jan 5, 2014
P4, N=210, Completed, Sponsor: Amgen
N=42 --> 32 Active, not recruiting --> Completed
- Trial termination: IVIG Treatment for Refractory Immune-Related Adult Epilepsy (clinicaltrials.gov) - Jan 4, 2014
P2, N=20, Terminated, Sponsor: Emory University
Active, not recruiting --> Completed Enrolling by invitation --> Terminated; Futility criteria, unable for Phase 2 of study, & phase 1 was terminated.
- Enrollment change: IVIG Treatment for Refractory Immune-Related Adult Epilepsy (clinicaltrials.gov) - Jan 4, 2014
P2, N=20, Terminated, Sponsor: Emory University
Enrolling by invitation --> Terminated; Futility criteria, unable for Phase 2 of study, & phase 1 was terminated. N=50 --> 20
- |||||||||| New P3 trial: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Jan 2, 2014
P3, N=70, Not yet recruiting, Sponsor: CSL Behring
- | Orencia (abatacept) / BMS
New P2 trial, P2 data: Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study (clinicaltrials.gov) - Jan 2, 2014
P2, N=15, Recruiting, Sponsor: Qingping Yao
- || Rinvoq (upadacitinib) / AbbVie
Clinical: A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 (clinicaltrials.gov) - Jan 2, 2014
P1, N=67, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=50 --> 20 N=85 --> 67
- Novolin R (recombinant human insulin) / Novo Nordisk
New P2 trial: Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia (clinicaltrials.gov) - Jan 2, 2014
P2, N=8, Not yet recruiting, Sponsor: Medical University of Graz
- ||| Rinvoq (upadacitinib) / AbbVie
Clinical: A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494 (clinicaltrials.gov) - Jan 2, 2014
P1, N=67, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=85 --> 67 Active, not recruiting --> Completed
- Promacta (eltrombopag) / Novartis
Trial completion: Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT (clinicaltrials.gov) - Jan 2, 2014
P2, N=30, Completed, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Counterregulatory Hormone Production in Adrenal Insufficiency and Diabetes Type I (clinicaltrials.gov) - Jan 2, 2014
P=N/A, N=40, Completed, Sponsor: University of Wuerzburg
Recruiting --> Completed Recruiting --> Completed
- Enrollment closed: DAP12WEGENER: Study of One Protein Implicated in Wegener Disease (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed Recruiting --> Active, not recruiting